Paediatric Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukaemia Cell Survival and Enhance Chemoresistance Via Contact-independent Mechanism

Overview

Journal Br J Haematol

Specialty Hematology

Date 2024 Nov 11

PMID 39523592

Authors

Alison Laing

Ahmed Elmarghany

Arwa A Alghaith

Aya Gouma

Thomas Stevens

Alexander Winton

Jennifer Cassels

Cassie J Clarke

Claire Schwab

Christine J Harrison

Brenda Gibson

Karen Keeshan

Affiliations

Soon will be listed here.

Abstract

Children diagnosed with acute myeloid leukaemia (paediatric AML [pAML]) have limited treatment options and relapse rates due to chemoresistance and refractory disease are over 30%. Current treatment is cytotoxic and in itself has long-lasting harsh side effects. New, less toxic treatments are needed. The bone marrow microenvironment provides chemoprotection to leukaemic cells through cell communication and interaction with mesenchymal stem cells (MSCs), but this is not well defined in pAML. Using primary patient material, we identify a cell contact-independent mechanism of MSC-mediated chemoprotection involving extrinsic soluble factors that is abrogated through inhibition of the JAK/STAT and ERK pathways.

Citing Articles

Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism.

Laing A, Elmarghany A, Alghaith A, Gouma A, Stevens T, Winton A Br J Haematol. 2024; 206(3):858-863.

PMID: 39523592 PMC: 11886936. DOI: 10.1111/bjh.19884.

References

Habbel J, Arnold L, Chen Y, Mollmann M, Bruderek K, Brandau S . Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro. Blood Adv. 2020; 4(13):3000-3010. PMC: 7362361. DOI: 10.1182/bloodadvances.2019001292. View

Kumar B, Garcia M, Weng L, Jung X, Murakami J, Hu X . Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2017; 32(3):575-587. PMC: 5843902. DOI: 10.1038/leu.2017.259. View

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H . Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019; 129(4):1596-1611. PMC: 6436863. DOI: 10.1172/JCI98785. View

Menendez P, Catalina P, Rodriguez R, Melen G, Bueno C, Arriero M . Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med. 2009; 206(13):3131-41. PMC: 2806455. DOI: 10.1084/jem.20091050. View

Duguid A, Mattiucci D, Ottersbach K . Infant leukaemia - faithful models, cell of origin and the niche. Dis Model Mech. 2021; 14(10). PMC: 8560498. DOI: 10.1242/dmm.049189. View

Borella G, Da Ros A, Borile G, Porcu E, Tregnago C, Benetton M . Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood. 2021; 138(7):557-570. DOI: 10.1182/blood.2020009845. View

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

Lu J, Dong Q, Zhang S, Feng Y, Yang J, Zhao L . Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling. Cancer Sci. 2023; 114(8):3287-3300. PMC: 10394133. DOI: 10.1111/cas.15855. View

Shafat M, Gnaneswaran B, Bowles K, Rushworth S . The bone marrow microenvironment - Home of the leukemic blasts. Blood Rev. 2017; 31(5):277-286. DOI: 10.1016/j.blre.2017.03.004. View

10.

Laing A, Elmarghany A, Alghaith A, Gouma A, Stevens T, Winton A . Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism. Br J Haematol. 2024; 206(3):858-863. PMC: 11886936. DOI: 10.1111/bjh.19884. View

11.

Urs A, Goda C, Kulkarni R . Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression. Ann Transl Med. 2024; 12(4):63. PMC: 11304419. DOI: 10.21037/atm-23-1824. View

12.

Stevens A, Miller J, Munoz J, Gaikwad A, Redell M . Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv. 2018; 1(18):1387-1397. PMC: 5727855. DOI: 10.1182/bloodadvances.2017007856. View

13.

Tremblay C, Ting S, McCluskey A, Robinson P, Curtis D . Shutting the gate: targeting endocytosis in acute leukemia. Exp Hematol. 2021; 104:17-31. DOI: 10.1016/j.exphem.2021.09.003. View

14.

Hou D, Wang B, You R, Wang X, Liu J, Zhan W . Stromal cells promote chemoresistance of acute myeloid leukemia cells via activation of the IL-6/STAT3/OXPHOS axis. Ann Transl Med. 2020; 8(21):1346. PMC: 7723653. DOI: 10.21037/atm-20-3191. View

15.

Miari K, Williams M . Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance. Br J Pharmacol. 2023; 181(2):216-237. DOI: 10.1111/bph.16028. View

16.

Ciciarello M, Corradi G, Loscocco F, Visani G, Monaco F, Cavo M . The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Front Oncol. 2019; 9:1135. PMC: 6823864. DOI: 10.3389/fonc.2019.01135. View